Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) have received an average recommendation of “Moderate Buy” from the nine ratings firms that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and eight have given a buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $64.4286.

A number of equities analysts recently weighed in on DNTH shares. Wedbush reaffirmed an “outperform” rating and set a $46.00 price objective on shares of Dianthus Therapeutics in a research report on Monday, December 22nd. HC Wainwright upped their price target on Dianthus Therapeutics from $40.00 to $47.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Wednesday, January 21st. Finally, Truist Financial boosted their price objective on Dianthus Therapeutics from $56.00 to $63.00 and gave the company a “buy” rating in a report on Thursday, January 8th.

Insider Activity

In other Dianthus Therapeutics news, CFO Ryan Savitz sold 20,000 shares of the business’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $45.18, for a total transaction of $903,600.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Simrat Randhawa sold 109,031 shares of the stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $38.14, for a total transaction of $4,158,442.34. Following the sale, the executive vice president directly owned 4,000 shares in the company, valued at $152,560. This represents a 96.46% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 216,538 shares of company stock valued at $8,283,175. 8.15% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Dianthus Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in DNTH. Fairmount Funds Management LLC increased its holdings in shares of Dianthus Therapeutics by 22.2% in the 3rd quarter. Fairmount Funds Management LLC now owns 3,307,191 shares of the company’s stock valued at $130,138,000 after acquiring an additional 600,000 shares during the last quarter. Vestal Point Capital LP boosted its holdings in Dianthus Therapeutics by 88.2% in the second quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock valued at $59,616,000 after purchasing an additional 1,499,931 shares in the last quarter. Wellington Management Group LLP increased its stake in Dianthus Therapeutics by 3,366.9% in the third quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock valued at $101,431,000 after purchasing an additional 2,503,311 shares during the last quarter. Vanguard Group Inc. raised its holdings in Dianthus Therapeutics by 24.7% during the fourth quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock worth $84,417,000 after purchasing an additional 406,254 shares in the last quarter. Finally, TCG Crossover Management LLC raised its holdings in Dianthus Therapeutics by 11.7% during the third quarter. TCG Crossover Management LLC now owns 1,676,624 shares of the company’s stock worth $65,975,000 after purchasing an additional 175,000 shares in the last quarter. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Trading Up 0.1%

Shares of DNTH opened at $53.39 on Friday. The company’s 50-day moving average price is $43.79 and its 200 day moving average price is $35.02. Dianthus Therapeutics has a 12-month low of $13.36 and a 12-month high of $57.50. The firm has a market cap of $2.31 billion, a P/E ratio of -15.34 and a beta of 1.55.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Wednesday, November 5th. The company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.11). The company had revenue of $0.40 million for the quarter, compared to analysts’ expectations of $0.58 million. Dianthus Therapeutics had a negative return on equity of 33.02% and a negative net margin of 4,106.04%. Equities research analysts forecast that Dianthus Therapeutics will post -2.61 earnings per share for the current year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.